Oculis Holding AG (OCS) Debt to Equity (2021 - 2023)
Quarterly Debt to Equity rose 100.0% to $0.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $0.0 through Dec 2023, up 100.0% year-over-year, with the annual reading at $0.0 for FY2023, 100.0% up from the prior year.
Oculis Holding AG's Debt to Equity history spans 3 years, with the latest figure at $0.0 for Q4 2023.
- Debt to Equity came in at $0.0 for Q4 2023, up from -$1.25 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.0 in Q4 2023 to a low of -$1.86 in Q4 2021.
- The 3-year median for Debt to Equity is -$1.25 (2022), against an average of -$1.04.
- Year-over-year, Debt to Equity skyrocketed 32.89% in 2022 and then skyrocketed 100.0% in 2023.
- Oculis Holding AG's Debt to Equity stood at -$1.86 in 2021, then surged by 32.89% to -$1.25 in 2022, then soared by 100.0% to $0.0 in 2023.
- Per Business Quant, the three most recent readings for OCS's Debt to Equity are $0.0 (Q4 2023), -$1.25 (Q4 2022), and -$1.86 (Q4 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 0.06 |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Oculis Holding AG | 24.51 Bn | 24.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 0.00 |
| Dec 31, 2022 | -1.25 |
| Dec 31, 2021 | -1.86 |